Biophytis Requests Pre-Submission Meeting With The FDA For Emergency Use Authorization Of Sarconeos (BIO101) For The Treatment Of COVID-19
Portfolio Pulse from Benzinga Newsdesk
Biophytis has requested a pre-submission meeting with the FDA for Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19.
July 20, 2023 | 5:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis' request for a pre-submission meeting with the FDA for Sarconeos (BIO101) could potentially expedite the drug's approval process, potentially impacting the company's stock positively.
The news of Biophytis seeking a pre-submission meeting with the FDA for Sarconeos (BIO101) is directly related to the company and its stock. If the FDA grants the meeting and subsequently approves the drug for emergency use, it could lead to increased revenues for Biophytis, potentially boosting its stock price. However, the outcome of the meeting and the FDA's decision are uncertain, hence the confidence score is not at the maximum.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100